BRIEF-Sarepta Therapeutics jumps in premarket after eteplirsen drug trial results
NEW YORK Oct 3 (Reuters) - Sarepta Therapeutics Inc : * Jumps 129.2 percent to $34.35 premarket after Duchenne Muscular Dystrophy drug eteplirsen trial results
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'
- Four dead in apparent Connecticut murder-suicide
- South Korea expands air defense zone to partially overlap China's |
- Singer Susan Boyle reveals she has Asperger's syndrome: paper
- Winter storm pushes up U.S. East Coast after deep-freeze in the South